Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Melanoma 1Locally Advanced Rectal Adenocarcinoma 1Liposarcoma 1Leiomyosarcoma 1Esophageal Neoplasms 1

Interventions

Doxorubicin 5brostallicin 2Sorafenib 2Radiation Dose Hypofractionation 2Nivolumab 2Ifosfamide 2Etoposide 2AZD 6244 2thymoglobulin 1tazemetostat 1sotigalimab 1selinexor 1romidepsin 1perifosine 1pembrolizumab 1pazopanib 1lorvotuzumab mertansine 1fludarabine phosphate 1exatecan 1decitabine and cedazuridine drug combination 1Trabectedin 1Thiotepa 1Temozolomide 1Tacrolimus 1Sunitinib 1Stem Cell Transplantation 1Specimen Handling 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurofibrosarcoma × sotigalimab × Clear all
NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

Columbia University

Phase 2 Active not recruiting
27 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡